Oncology Institute IncTOI
Price$5.13

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $587.2M+49.3% YoYTTM through 30 Jun 2026
Net Income -$36.3MTTM through 30 Jun 2026
Free Cash Flow -$3.3MTTM through 30 Jun 2026

Margins

Current
Gross Margin15.8%
EBITDA Margin-3.3%
Operating Margin-4.4%
Net Margin-6.2%

Returns

-386.4%ROE
-26.0%ROA

Balance Sheet Health

Debt / Equity-4.83x
Current Ratio1.59x
Net Debt$48.3M
Cash & Equivalents$41.1M

Quality Metrics

Altman Z-Score2.33
Piotroski F-Score5 / 9
FCF Margin-0.6%
Rule of 4011.1
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'20'21'22'23'24'25
FY2025: $502.7M
Diluted EPS-$0.29TTM
'20'21'22'23'24'25
FY2025: $-0.66

Dividend

No dividend

Capital Allocation

Capex Intensity0.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.